Clinical trials: Intestinal Obstruction
- Condition Intestinal Obstruction
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Irritable Bowel Syndrome
Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety…
- Trial name
- NCT01633723
- Testing
- DA-6886
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Infections, Rotavirus
Special Drug Use Investigation for ROTARIX®
This study aims to determine the incidence of intussusceptions (IS) (including suspected cases of intussusception) after vaccination with Oral Rotarix® under clinical practice, in Japan.
- Trial name
- NCT01636739
- Testing
- Oral Rotarix®, Data collection
- Volunteers
- 10,982 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Celiac Disease, Gluten Sensitivity
Bovine Colostrum to Prevent Absorption of Gluten
To investigate the use of hyperimmune bovine colostrum to reduce gluten absorption. A double-blind, cross-over study will be performed in which persons who are following a strict gluten-free diet will be challenged with oral…
- Conditions
- Celiac Disease, Gluten Sensitivity, Non-celiac Gluten Sensitivity
- Trial name
- NCT05555446
- Testing
- Bovine colostrum
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Milky Way Life Sciences LLC
Postoperative Complications, Constipation
Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects
This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of…
- Trial name
- NCT00311350
- Testing
- MOA-728
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Infections, Rotavirus
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of GSK Biologicals' oral live attenuated HRV vaccine (Rotarix) in the primary vaccination study (102247).
- Trial name
- NCT00420316
- Testing
- Rotarix (primary vaccination study)
- Where
- 15 sites in Finland
- Volunteers
- 1,613 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline